Correspondence 0001104659-25-027326 from Jade Biosciences, Inc. (JBIO)
Jade Biosciences, Inc.
Date: March 24, 2025 · CIK: 0001798749 · Accession: 0001104659-25-027326
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283562
Letter
Aerovate Therapeutics, Inc.
930 Winter Street, Suite M-500
Waltham, MA 02451
March 24, 2025
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street NE
Washington, DC 20549
Attention: Ms. Jessica Dickerson
Mr. Chris Edwards
Ms. Tara Harkins
Ms. Sasha Parikh
Re: Aerovate Therapeutics, Inc.
Acceleration Request for Registration Statement on Form S-4
File No. 333-283562
Requested Date: March 25, 2025
Requested Time: 4:15 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aerovate Therapeutics, Inc. (the " Company ") hereby requests that the effective date of the above-referenced registration statement (the " Registration Statement ") be accelerated to March 25, 2025, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless the Company requests by telephone that such Registration Statement be declared effective at some other time. The Company hereby authorizes each of Edwin O'Connor, Tevia K. Pollard and Alicia Tschirhart of Goodwin Procter LLP, counsel to the Company, to make such request on its behalf.
Once the Registration Statement is effective, please orally confirm the event with the Company's counsel, Goodwin Procter LLP by calling Edwin O'Connor at (212) 813-8853. The Company also respectfully requests that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to the Company's counsel, Goodwin Procter LLP, Attention: Edwin O'Connor, by email to eoconnor@goodwinlaw.com .
If you have any questions regarding this request, please contact Edwin O'Connor of Goodwin Procter LLP at (212) 813-8853.
* * *
Sincerely,
Aerovate
Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm Aerovate Therapeutics, Inc. 930 Winter Street, Suite M-500 Waltham, MA 02451 March 24, 2025 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Attention: Ms. Jessica Dickerson Mr. Chris Edwards Ms. Tara Harkins Ms. Sasha Parikh Re: Aerovate Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-4 File No. 333-283562 Requested Date: March 25, 2025 Requested Time: 4:15 p.m. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aerovate Therapeutics, Inc. (the " Company ") hereby requests that the effective date of the above-referenced registration statement (the " Registration Statement ") be accelerated to March 25, 2025, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless the Company requests by telephone that such Registration Statement be declared effective at some other time. The Company hereby authorizes each of Edwin O'Connor, Tevia K. Pollard and Alicia Tschirhart of Goodwin Procter LLP, counsel to the Company, to make such request on its behalf. Once the Registration Statement is effective, please orally confirm the event with the Company's counsel, Goodwin Procter LLP by calling Edwin O'Connor at (212) 813-8853. The Company also respectfully requests that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to the Company's counsel, Goodwin Procter LLP, Attention: Edwin O'Connor, by email to eoconnor@goodwinlaw.com . If you have any questions regarding this request, please contact Edwin O'Connor of Goodwin Procter LLP at (212) 813-8853. * * * Sincerely, Aerovate Therapeutics, Inc. By: /s/ Timothy Noyes Timothy Noyes Chief Executive Officer cc: Edwin O'Connor, Goodwin Procter LLP Tevia K. Pollard, Goodwin Procter LLP Alicia Tschirhart, Goodwin Procter LLP George Eldridge, Aerovate Therapeutics, Inc. Ryan A. Murr, Gibson, Dunn & Crutcher LLP Branden C. Berns, Gibson, Dunn & Crutcher LLP